Use of Stromal Intervention and Exogenous Neoantigen Vaccination to Boost Pancreatic Cancer Chemo-Immunotherapy by Nanocarriers
Despite the formidable treatment challenges of pancreatic ductal adenocarcinoma (PDAC), considerable progress has been made in improving drug delivery via pioneering nanocarriers. These innovations are geared towards overcoming the obstacles presented by dysplastic stroma and fostering anti-PDAC imm...
Main Authors: | Saborni Chattopadhyay, Yu-Pei Liao, Xiang Wang, André E. Nel |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-10-01
|
Series: | Bioengineering |
Subjects: | |
Online Access: | https://www.mdpi.com/2306-5354/10/10/1205 |
Similar Items
-
Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1
by: Xiangsheng Liu, et al.
Published: (2021-03-01) -
Tertiary lymphoid structures in pancreatic cancer: a new target for immunotherapy
by: Xinlei Zou, et al.
Published: (2023-07-01) -
Genomic Landscape in Neoplasm-Like Stroma Reveals Distinct Prognostic Subtypes of Pancreatic Ductal Adenocarcinoma
by: Jiahong Jiang, et al.
Published: (2021-10-01) -
Surgical treatment of micronodular thymoma with lymphoid stroma
by: Min Kyun Kang, et al.
Published: (2020-04-01) -
Pancreatic fibrosis, acinar atrophy and chronic inflammation in surgical specimens associated with survival in patients with resectable pancreatic ductal adenocarcinoma
by: Taija Korpela, et al.
Published: (2022-01-01)